Evidence map›Paper›PMID 33442544›Full record

ArticleLiver cancer2020

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.

Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, Yuta Kobayashi, Satoshi Okubo, Licht Tominaga, Akira Kajiwara, Kayoko Kasuya, Soichi Iritani, Shunichiro Fujiyama and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Lenvatinib, sintilimab combined interventional treatmentWorld journal of gastroenterology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Yusuke KawamuraDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Masahiro KobayashiDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Junichi ShindohOkinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Yuta KobayashiOkinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Satoshi OkuboOkinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Licht TominagaOkinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Akira KajiwaraDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Kayoko KasuyaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Soichi IritaniDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Shunichiro FujiyamaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Tetsuya HosakaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Satoshi SaitohDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Hitomi SezakiDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Norio AkutaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Fumitaka SuzukiDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Yoshiyuki SuzukiDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Kenji IkedaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Yasuji AraseDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Masaji HashimotoOkinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Tokuyo KozukaOkinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan.
Hiromitsu KumadaDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.
Toranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aims of this study were to evaluate the efficacy of additional treatment, especially lenvatinib-transarterial chemoembolization (TACE) sequential therapy, for unresectable hepatocellular carcinoma (HCC).

methodsConsecutive 56 patients who underwent lenvatinib treatment were reviewed. Oncological aggressiveness of tumor was estimated using a dynamic CT enhancement pattern classification, and clinical impact of subsequent treatment was investigated through analysis of progression-free survival (PFS), post-progression survival (PPS), and multivariate analysis of potential confounders for survival after progression during lenvatinib therapy.

resultsHeterogeneous enhancement patterns (

conclusionOncological aggressiveness of HCC estimated by CT enhancement pattern was predictive of PPS after progression during lenvatinib. Successful subsequent treatment with lenvatinib-TACE sequential therapy may offer survival benefit regardless of CT enhancement pattern of HCC.

Indexed as

Hepatocellular carcinomaLenvatinibLenvatinib-transarterial chemoembolization sequential therapyOncological aggressivenessSubsequent treatment

Identifiers

PMID33442544
PMCPMC7768146
OpenAlexW3096245719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.